SG Americas Securities LLC Has $868,000 Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

SG Americas Securities LLC boosted its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) by 1,115.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,751 shares of the company’s stock after purchasing an additional 30,975 shares during the quarter. SG Americas Securities LLC’s holdings in Vir Biotechnology were worth $868,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Vir Biotechnology by 8.8% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,184 shares of the company’s stock valued at $236,000 after purchasing an additional 740 shares during the period. Advisor Group Holdings Inc. boosted its stake in Vir Biotechnology by 9.4% during the 4th quarter. Advisor Group Holdings Inc. now owns 9,826 shares of the company’s stock valued at $397,000 after purchasing an additional 846 shares during the period. Nisa Investment Advisors LLC boosted its stake in Vir Biotechnology by 186.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,430 shares of the company’s stock valued at $49,000 after purchasing an additional 930 shares during the period. Dupont Capital Management Corp boosted its stake in Vir Biotechnology by 24.4% during the 1st quarter. Dupont Capital Management Corp now owns 5,175 shares of the company’s stock valued at $133,000 after purchasing an additional 1,014 shares during the period. Finally, DekaBank Deutsche Girozentrale boosted its stake in Vir Biotechnology by 2.9% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 39,200 shares of the company’s stock valued at $1,533,000 after purchasing an additional 1,100 shares during the period. Institutional investors own 79.91% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $125.00 price objective on shares of Vir Biotechnology in a report on Thursday, July 14th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus target price of $61.33.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director Saira Ramasastry sold 1,687 shares of Vir Biotechnology stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $23.82, for a total value of $40,184.34. Following the completion of the transaction, the director now owns 8,092 shares in the company, valued at approximately $192,751.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Vicki L. Sato sold 14,541 shares of the business’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $20.62, for a total transaction of $299,835.42. Following the completion of the sale, the director now owns 1,503,463 shares in the company, valued at $31,001,407.06. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Saira Ramasastry sold 1,687 shares of the business’s stock in a transaction on Tuesday, May 24th. The stock was sold at an average price of $23.82, for a total value of $40,184.34. Following the sale, the director now owns 8,092 shares of the company’s stock, valued at approximately $192,751.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,049 shares of company stock worth $1,747,779. 22.40% of the stock is currently owned by insiders.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $27.81 on Monday. The company has a market capitalization of $3.68 billion, a PE ratio of 3.07 and a beta of -0.45. Vir Biotechnology, Inc. has a one year low of $18.21 and a one year high of $58.00. The business has a 50 day simple moving average of $26.48 and a 200 day simple moving average of $26.33.

Vir Biotechnology (NASDAQ:VIRGet Rating) last posted its earnings results on Thursday, May 5th. The company reported $3.85 EPS for the quarter, topping the consensus estimate of $3.21 by $0.64. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $811.05 million. Vir Biotechnology had a return on equity of 96.39% and a net margin of 52.29%. Vir Biotechnology’s revenue was up 59900.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.32) EPS. Equities analysts anticipate that Vir Biotechnology, Inc. will post 2.06 earnings per share for the current fiscal year.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Featured Stories

Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating).

Institutional Ownership by Quarter for Vir Biotechnology (NASDAQ:VIR)

Want More Great Investing Ideas?

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.